Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint; Jill M. Kolesar; Joseph Robert McCorkle; Jianrong Wu; Carleton S. Ellis; Danielle E. Otto; Peng Wang

doi:10.12659/MSM.938091

14 October 2022 : Clinical Research

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint^12ABCDEFG*, Jill M. Kolesar^23CDE, Joseph Robert McCorkle^2CDE, Jianrong Wu^4C, Carleton S. Ellis^32CDE, Danielle E. Otto^23CDE, Peng Wang^12ACDE

DOI: 10.12659/MSM.938091

Med Sci Monit 2022; 28:e938091

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 5 Correlation between 1-month, 3-month, and 7-month abiraterone trough levels and prostate-specific antigen alteration (change from baseline to 1 month of starting treatment).

Correlation (PSA alternation, AA)	Spearman rank correlation	P value
1 Month	0.372	0.259
3 Months	0.183	0.637
7 Months	0.200	0.704
PSA alteration, change of PSA from baseline to 1 month after treatment; AA – abiraterone acetate.

Back to the Article

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Your Privacy